Skip to content Skip to footer
PharmaShots' Most Read News of 2019

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…

Read more

Insights+ Key Biosimilars Events of November 2019

Insights+ Key Biosimilars Events of November 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…

Read more

Biosimilar Companies Top 20 2018

Top Biosimilar Companies with Approved and Pipeline Products in the US and EU

​ Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency- safety- and efficacy to original biologic products. The companies are focusing…

Read more